Anti-pd-l1 antibodies and methods of making and using thereof

A technology of PD-L1 and antibody, applied in the field of preparation of anti-PD-L1 antibody

Active Publication Date: 2020-02-21
SYSTIMMUNE INC +1
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Negative secondary signaling can lead to T cell suppression and tolerance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-pd-l1 antibodies and methods of making and using thereof
  • Anti-pd-l1 antibodies and methods of making and using thereof
  • Anti-pd-l1 antibodies and methods of making and using thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] Example 1: Production of anti-PD-L1 antibodies

[0085] A monoclonal antibody against human PD-L1 was developed by immunizing New Zealand white rabbits. Initial immunizations were performed subcutaneously with 100 μg recombinant human PD-L1 ectodomain mixed 1:1 v / v in complete Freund's adjuvant. This was followed by booster immunizations at weeks 3, 6, 9 and 10 with 50 μg of antigen in incomplete Freund's adjuvant. In addition to antigen, at weeks 6, 9 and 10, 1×10 6 Animals were boosted with HEK-293 cells that were transiently transfected to express full-length human PD-L1.

[0086] At weeks 9 and 12, sera from animals were tested for anti-PD-L1 titers by ELISA. 96-well plates were passively adsorbed overnight at 4°C with goat anti-rabbit IgG antibody (Jackson ImmunoResearch). The coated wells were washed and blocked with 1% milk for 1 hour at room temperature, and then incubated with human PD-L1 extracellular domain-human Fc domain fusion protein for 1 hour at r...

Embodiment 2

[0097] Example 2: Binding affinity of anti-PD-L1 antibodies

[0098] Binding kinetics of selected anti-PD-L1 antibodies AB1-AB5 and AB1HU-AB5HU were determined by biolayer interferometry on a Fortebio Octbe Red 96 instrument. First, purified antibodies were produced by protein A chromatography using antibody supernatants transiently transfected with HEK-293. The assay was performed by immobilizing purified antibodies onto anti-human Fc biosensors. The association and dissociation of PD-L1 to the biosensor was then observed at various concentrations of PD-L1. Specifically, eight anti-human Fc biosensors were placed in wells containing the same purified antibody for 5 minutes. The biosensor was equilibrated for 1 min in kinetic buffer (Pall Fortebio) to establish a baseline. PD-L1 association was observed by placing the biosensor in wells containing various concentrations of human PD-L1 ectodomain for 5 min. Dissociation was measured after transferring the biosensor to kin...

Embodiment 3

[0102] Example 3: Antibodies that bind to PD-L1 expressed on the cell surface

[0103] Human lung cancer cell line H441 was labeled with FVS520 reactive dye (BD Biosciences, diluted 1:2000) for 15 min at room temperature. Labeled cells were then diluted in FACS buffer (2% FBS in PBS), added to V-bottom 96-well plates (50,000 cells per well) and incubated with 0-100 nM anti-huPDL1 or negative control isotype Matched or positive control isotype-matched control antibodies were incubated on ice for 30 min. Cells were washed to remove excess primary antibody and then labeled with Alex Fluor647-conjugated goat anti-human Fc secondary antibody (Jackson ImmunoResearch, 1:1600 dilution). Cells were incubated on ice for 20 min and then washed with FACS buffer before acquisition on a FACSCalibur flow cytometer equipped with a Cytek AMS plate loading system. Figure 5 Median fluorescence intensity (MFI) on the AF647 channel after gating on live cells is shown. Error bars represent SE...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
Login to view more

Abstract

The present application provides anti-PD-L1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and / or nucleic acids encoding the same, and their use to upregulate T cell function in the treatment of cancer and other T cell dysfunctions to enhance cell-mediated immune responses.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Patent Application No. 62524553, filed June 25, 2017, which is expressly incorporated herein by reference in its entirety. technical field [0003] The present disclosure generally relates to the technical field of antibodies, and more specifically relates to the preparation and use of anti-PD-L1 antibodies. Background technique [0004] Cancer is a major health problem worldwide. In the United States alone, an estimated 1,685,210 new cancer cases were diagnosed and 595,690 deaths occurred in 2016 (http: / / www.cancer.gov). Therefore, any agent that reduces cancer severity or mortality is desirable. [0005] In the immune system, resting T cells can be activated in response to antigens by primary signals delivered by foreign antigenic peptides presented by antigen-presenting cells (APCs) through T-cell receptors (TCRs). In addition to this primary signal, there a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/13A61K47/68A61P35/00
CPCC07K16/2827A61K45/06A61P35/00C07K2317/565C07K2317/56C07K2317/24C07K2317/51C07K2317/515C07K2317/92C07K2317/73C07K2317/76A61K39/39541C07K2317/31
Inventor 布莱恩·科瓦切维奇夏冬安妮·詹森乔恩·法莱布莱尔·伦肖杰弗里·B·阿达莫菲尔·谭高泽人朱义
Owner SYSTIMMUNE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap